Acquisition by Charles Theuer of 4500 shares of TRACON Pharmaceuticals at 1.85 subject to Rule 16b-3

Read at macroaxis.com

Published over six months ago View all stories for TRACON Pharmaceuticals | TRACON Pharmaceuticals Hype Analysis

Acquisition of 4500 common stock at 1.85 of TRACON Pharmaceuticals by Charles Theuer on 11th of March 2024. This event was filed by TRACON Pharmaceuticals with SEC on 2022-07-22. Statement of changes in beneficial ownership - SEC Form 4

We analyze TRACON Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TRACON Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TRACON Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TRACON Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of TRACON Pharmaceuticals could also be used in its relative valuation, which is a method of valuing TRACON Pharmaceuticals by comparing valuation metrics with similar companies.

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Stocks Directory module to find actively traded stocks across global markets.

If you are still planning to invest in TRACON Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the TRACON Pharmaceuticals' history and understand the potential risks before investing.